Shenzhen Second People's Hospital

Running trials

• Not yet recruiting

  Long-term Safety of BR005-036C Tablets in the Acute Treatment of Migraine in Adults

  NCT07835152· Phase 3· Brise Pharmaceuticals Co., Ltd.· Source

• Not yet recruiting

  A Phase 3 Study of Povorcitinib Phosphate in Chinese Adults With Nonsegmental Vitiligo

  NCT07865312· Phase 3· Dermavon Holdings Limited· Source

• Not yet recruiting

  Real-world Study of the Effectiveness and Tolerability of Outpatient Titration of OxyContin for the Moderate and Severe Pain in Cancer Patients

  NCT07869797· Mundipharma (China) Pharmaceutical Co. Ltd· Source

• Recruiting

  Efficacy and Safety of BR005-036C Tablets for the Acute Treatment of Migraine in Adults

  NCT07792681· Phase 2/3· Brise Pharmaceuticals Co., Ltd.· Source

• Recruiting

  A Clinical Trial of TQH3906 Capsules in Adult Patients With Moderate to Severe Plaque Psoriasis

  NCT07724366· Phase 3· Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.· Source

• Recruiting

  A Clinical Trial of TQH3906 Capsules in the Treatment of Active Psoriatic Arthritis

  NCT07406035· Phase 2· Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.· Source

• Recruiting

  A Clinical Trial on the Efficacy and Safety of TQH3906 in the Treatment of Systemic Lupus Erythematosus

  NCT07509892· Phase 2· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source

• Not yet recruiting

  Zanubrutinib Induction Followed by Delayed Fixed-Duration Combination With Sonrotoclax for CLL/SLL：Stop Trial 2.0

  NCT07682415· Phase 2· Yi Shuhua· Source

• Not yet recruiting

  Becotatug Vedotin Combined With Pucotenlimab as Neoadjuvant Therapy for Resectable Recurrent Head and Neck Squamous Cell Carcinoma After Progression on Immunotherapy: A Prospective Phase II Study

  NCT07589049· Phase 2· Sun Yat-sen University· Source

• Enrolling by invitation

  BRIDGE Study: Neoadjuvant Finotonlimab, Cetuximab, and Docetaxel in Resectable Recurrent HNSCC After Immunotherapy Progression

  NCT07618624· Phase 2· Sun Yat-sen University· Source

• Not yet recruiting

  A Exploratory Study on Untreated Follicular Lymphoma With Orelabrutinib, Tafasitamab, and Lenalidomide

  NCT07585747· Phase 2· Institute of Hematology & Blood Diseases Hospital, China· Source

• Recruiting

  A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma

  NCT07297212· Phase 2· BioNTech SE· Source

• Recruiting

  Efficacy and Safety of the KPCXM18 Injection in Patients With Acute Ischemic Stroke

  NCT07279493· Phase 2· Kunming Pharmaceuticals, Inc.· Source

• Recruiting

  A Clinical Study to Evaluate the Safety, Tolerability and Efficacy of BBM-A101 in the Treatment of Knee Osteoarthritis.

  NCT07198555· Phase 1· Belief BioMed (Beijing) Co., Ltd· Source

• Recruiting

  A Study of VRT106 for Injection in Patients With Recurrent/Progressive Glioblastoma

  NCT07093814· Phase 1/2· Guangzhou Virotech Pharmaceutical Co., Ltd.· Source

• Recruiting

  Efficacy of Glycemic Improvement Project (GLITTER Study) in Type 1 Diabetes-GLITTER Study 2

  NCT07097818· Second Xiangya Hospital of Central South University· Source

• Recruiting

  A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

  NCT06852222· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  The Efficacy and Safety of Efsubaglutide Alfa Injection in Overweight and Obese Subjects (ENLIGHT)

  NCT06921486· Phase 2/3· Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.· Source

• Active, not recruiting

  Phase III Clinical Trial of STSP-0601 for Injection in Hemophilia Patients

  NCT06922045· Phase 3· Jiangsu BioJeTay Biotechnology Co., Ltd.· Source

• Not yet recruiting

  Clinical Trial of TQB3702 Tablets in Subjects With Systemic Lupus Erythematosus (SLE)

  NCT06859931· Phase 2· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source

• Recruiting

  Effects of Inspiratory Muscle Training on Stroke Rehabilitation Outcomes

  NCT06640101· Hong Kong Metropolitan University· Source

• Recruiting

  Glycemic Improvement With Team, Technology, Education and Peer Resources in Type 1 Diabetes-GLITTER Study

  NCT07097805· Second Xiangya Hospital of Central South University· Source

• Active, not recruiting

  Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML

  NCT06578247· Phase 3· Daiichi Sankyo· Source

• Recruiting

  ICP-332 in Subjects With Moderate to Severe Atopic Dermatitis

  NCT06775860· Phase 3· Beijing InnoCare Pharma Tech Co., Ltd.· Source

• Recruiting

  IMM01+Azacitidine VS Placebo +Azacitidine in Patients With Newly Diagnosed Chronic Myelomonocytic Leukemia (CMML1-2)

  NCT06647862· Phase 3· ImmuneOnco Biopharmaceuticals (Shanghai) Inc.· Source

• Recruiting

  Early Antiplatelet Administration After Intravenous Thrombolysis for Acute Ischemic Stroke (TREND-IVT)

  NCT06548971· Phase 3· Capital Medical University· Source

• Recruiting

  Remote Ischemic Conditioning for Acute Ischemic Stroke Treated With Mechanical Thrombectomy（RECAST-MT）

  NCT06559241· Phase 3· Capital Medical University· Source

• Recruiting

  Randomized Study of ABC-14 Regimen Compared With "3+7" Standard Induction Therapy or AB-14 for ND AML

  NCT06451861· Phase 2· Guangdong Provincial People's Hospital· Source

• Recruiting

  A Clinical Trial of TQB2102 for Injection in Non-small Cell Lung Cancer With HER2 Gene Abnormality

  NCT06496490· Phase 2· Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.· Source

• Not yet recruiting

  Henagliflozin's Impact on Prediabetes Remission

  NCT06448130· Phase 4· Shandong Provincial Hospital· Source

• Recruiting

  A Study to Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid Leukemia

  NCT06387069· Phase 3· Hutchmed· Source

• Not yet recruiting

  Investigator-initiated Phase I Exploratory Clinical Study of the Safety, Tolerability, and Efficacy of BST02 Injection in the Treatment of Locally Advanced/Metastatic Liver Cancer

  NCT06173726· Early phase 1· BioSyngen Pte Ltd· Source

• Recruiting

  A Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma

  NCT06049290· Phase 1/2· Nanjing Leads Biolabs Co.,Ltd· Source

• Active, not recruiting

  A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus

  NCT05531565· Phase 2/3· Biogen· Source

• Recruiting

  China HeadAche DIsorders RegiStry

  NCT05334927· Beijing Tiantan Hospital· Source

• Active, not recruiting

  A Study of GNC-038, a Tetra-specific Antibody, in Participants With R/R Diffuse Large B-cell Lymphoma (DLBCL)

  NCT05192486· Phase 1/2· Sichuan Baili Pharmaceutical Co., Ltd.· Source

• Active, not recruiting

  Study to Assess Adverse Events and Change in Disease State of Oral Venetoclax in Combination With Subcutaneous (SC) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy in China

  NCT05144243· Phase 4· AbbVie· Source

• Recruiting

  China Diabetes Type 1 Study (CD1S) by China Alliance for Type 1 Diabetes

  NCT05498974· Second Xiangya Hospital of Central South University· Source

• Active, not recruiting

  Evaluation of the Safety and Efficacy of Hemophilia B Gene Therapy Drug

  NCT05203679· Phase 2/3· Shanghai Xinzhi BioMed Co., Ltd.· Source

• Active, not recruiting

  SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies

  NCT04684108· Phase 1· Hangzhou Sumgen Biotech Co., Ltd.· Source

• Active, not recruiting

  A Study to Access Efficacy and Safety of P1101 in Chinese PV Patients Who Are Intolerant or Resistance to HU

  NCT05485948· Phase 2· PharmaEssentia· Source

• Recruiting

  A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments

  NCT05020236· Phase 3· Pfizer· Source

• Active, not recruiting

  A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

  NCT04975308· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  A Clinical Study to Evaluate the Long-Term Safety Sodium Oligomannate Capsules (GV-971)

  NCT05058040· Phase 4· Green Valley (Shanghai) Pharmaceuticals Co., Ltd.· Source

• Recruiting

  Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

  NCT03936153· Phase 2· Xynomic Pharmaceuticals, Inc.· Source

• Recruiting

  Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia

  NCT04143724· Phase 2· Celgene· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Stroke4 recruiting
• Acute myeloid leukaemia3 recruiting
• Migraine3 recruiting
• Type 1 diabetes3 recruiting
• Glioblastoma2 recruiting
• Head and neck cancer2 recruiting
• Lupus (SLE)2 recruiting
• Multiple myeloma2 recruiting
• Psoriasis2 recruiting
• Type 2 diabetes2 recruiting
• Atopic dermatitis (eczema)1 recruiting
• Chronic lymphocytic leukaemia1 recruiting
• Chronic myeloid leukaemia1 recruiting
• Diffuse large B-cell lymphoma1 recruiting
• Follicular lymphoma1 recruiting
• Liver and biliary tract cancer1 recruiting
• Lung cancer1 recruiting
• Osteoarthritis1 recruiting
• Psoriatic arthritis1 recruiting
• Thalassaemia1 recruiting
• Vitiligo1 recruiting

Closed trials

• Completed

  A Phase III Trial To Evaluate The Efficacy And Safety Of MC2-01 Cream Compared To CAL/BDP Gel and Vehicle In Plaque Psoriasis Subjects

  NCT07357831· Phase 3· Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.· Source

• Completed

  A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Chronic Kidney Disease

  NCT06926660· Phase 2· Boehringer Ingelheim· Source

• Completed

  HPP737 in Adult Patients With Plaque Psoriasis

  NCT07712731· Phase 3· Newsoara Biopharma Co., Ltd.· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of AK120 in Subjects With Moderate to Severe Atopic Dermatitis

  NCT06700499· Phase 2· Akeso· Source

• Recruiting

  Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)

  NCT05485961· Phase 2/3· CSL Behring· Source

• Completed

  Safety and Efficacy of STSP-0601 in Adult Patients with Hemophilia a or B with Inhibitor

  NCT06289166· Phase 2· Staidson (Beijing) Biopharmaceuticals Co., Ltd· Source

• Completed

  The Effects of Inspiratory Pressures on Diaphragmatic Contraction in People After Stroke

  NCT06267768· Hong Kong Metropolitan University· Source

• Completed

  A Clinical Study of JS005 in Patients With Ankylosing Spondylitis

  NCT06250062· Phase 2· Shanghai Junshi Bioscience Co., Ltd.· Source

• Completed

  Phase 3 Clinical Project of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion Protein

  NCT06142552· Phase 3· Hangzhou Gensciences Biopharmaceutical Co., Ltd.· Source

• Completed

  A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis

  NCT06068465· Phase 3· Tasly Pharmaceutical Group Co., Ltd· Source

• Completed

  Efficacy and Safety of Minocycline in Patients With Moderate to Severe Acute Ischemic Stroke

  NCT05836740· Phase 3· Beijing Tiantan Hospital· Source

• Terminated

  A Phase 3 Clinical Study to Evaluate Lemzoparlimab for Injection in Combination With Azacitidine (AZA) Versus AZA Monotherapy in Treatment-naïve Patients With Higher-risk Myelodysplastic Syndrome (MDS)

  NCT05709093· Phase 3· TJ Biopharma Co., Ltd.· Source

• Completed

  A Study of Adynovate in Previously Treated Chinese Teenagers and Adults With Severe Hemophilia A

  NCT05707351· Phase 3· Takeda· Source

• Completed

  HFNO Improves Blood Oxygen Saturation During Asphyxia During Pulmonary Surgery With Double-lumen Endotracheal Intubation

  NCT05666908· Shenzhen Second People's Hospital· Source

• Completed

  Chinese Osteoporotic Fracture Registration Network Platform

  NCT05339425· Peking Union Medical College Hospital· Source

• Completed

  Phase III Study on HMPL-523 for Treatment of ITP

  NCT05029635· Phase 3· Hutchmed· Source

• Completed

  Effectiveness and Safety of Directional Deep Brain Stimulation for Parkinson's Disease

  NCT05992701· Beijing Pins Medical Co., Ltd· Source

• Completed

  A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)

  NCT04939142· Phase 3· Antengene Corporation· Source

• Completed

  A Trial of Enzastaurin Plus Temozolomide During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma With or Without the Novel Genomic Biomarker, DGM1

  NCT03776071· Phase 3· Denovo Biopharma LLC· Source

• Completed

  The Study for CML Who Failed Prior TKIs or With T315I Mutation or Ph+ ALL Who Failed Prior TKIs or With T315I Mutation

  NCT04233346· Phase 2· Otsuka Beijing Research Institute· Source

• Completed

  A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of TJ011133 as Monotherapy and in Combination With Azacitidine (AZA) in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

  NCT04202003· Phase 1/2· TJ Biopharma Co., Ltd.· Source

• Completed

  A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase

  NCT04126681· Phase 2· Ascentage Pharma Group Inc.· Source

• Completed

  ADVATE/ ADYNOVI Hemophilia A Outcome Database (AHEAD)

  NCT02078427· Baxalta now part of Shire· Source